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Multifaceted intervention to enhance cognition in older people at risk of
cognitive decline: Study protocol for the Protein Omega-3 and Vitamin D
Exercise Research (PONDER) study
Abstract

Introduction An increasing number of people are living with cognitive impairment and dementia. Current
pharmacological therapies at best reduce Alzheimer's disease symptomatology but do not delay dementia
onset in those at high risk. Structured exercise interventions can enhance cognition in older people; however,
to produce long lasting, clinically relevant cognitive benefits, it is proposed that a multifaceted approach
incorporating exercise with dietary supplements will address a wider range of mechanisms involved in
cognitive decline. The Protein Omega-3 aNd vitamin D Exercise Research (PONDER) study aims to
investigate the cognitive effects of a multimodal exercise programme combined with nutritional
supplementation in older adults with subjective memory impairment (SMI).
Methods and analysis The PONDER study is a single-centre, 12-month, community-based, parallel group,
randomised, double-blind, placebo controlled trial involving a 6-month multifaceted intervention with a
further 6-month follow-up. Participants will be 148 people from Melbourne, Australia, aged 60-85 years with
SMI who will be randomised (1:1 ratio) to either a 6-month supervised multimodal exercise programme
combined with omega-3 fatty acid, vitamin D and protein supplementation or a stretching/flexibility exercise
programme combined with placebo supplements. The primary outcome is the change in cognition after 6
months as assessed by the Trail Making Test and global cognitive function assessed from the Cogstate
Computerised battery. Secondary outcomes will include memory, working memory/learning and attention/
psychomotor function, the Montreal Cognitive Assessment, mood, quality of life, muscle strength, physical
function, body composition, cardiovascular health and sleep quality. Cognition at 12 months will represent a
secondary outcome.
Ethics and dissemination This study has been approved by the Deakin University Human Research Ethics
Committee (project 2016-260). Informed consent will be obtained from all participants. The authors intend
to submit the findings of the study to peer-reviewed journals or academic conferences to be published.
Trial registration number ACTRN12616001549415; Pre-results.
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Abstract
Introduction An increasing number of people are
living with cognitive impairment and dementia. Current
pharmacological therapies at best reduce Alzheimer’s
disease symptomatology but do not delay dementia onset
in those at high risk. Structured exercise interventions can
enhance cognition in older people; however, to produce
long lasting, clinically relevant cognitive benefits, it is
proposed that a multifaceted approach incorporating
exercise with dietary supplements will address a wider
range of mechanisms involved in cognitive decline.
The Protein Omega-3 aNd vitamin D Exercise Research
(PONDER) study aims to investigate the cognitive effects
of a multimodal exercise programme combined with
nutritional supplementation in older adults with subjective
memory impairment (SMI).
Methods and analysis The PONDER study is a singlecentre, 12-month, community-based, parallel group,
randomised, double-blind, placebo controlled trial involving
a 6-month multifaceted intervention with a further
6-month follow-up. Participants will be 148 people from
Melbourne, Australia, aged 60–85 years with SMI who will
be randomised (1:1 ratio) to either a 6-month supervised
multimodal exercise programme combined with omega-3
fatty acid, vitamin D and protein supplementation or a
stretching/flexibility exercise programme combined with
placebo supplements. The primary outcome is the change
in cognition after 6 months as assessed by the Trail Making
Test and global cognitive function assessed from the
Cogstate Computerised battery. Secondary outcomes will
include memory, working memory/learning and attention/
psychomotor function, the Montreal Cognitive Assessment,
mood, quality of life, muscle strength, physical function,
body composition, cardiovascular health and sleep
quality. Cognition at 12 months will represent a secondary
outcome.
Ethics and dissemination This study has been approved
by the Deakin University Human Research Ethics
Committee (project 2016–260). Informed consent will
be obtained from all participants. The authors intend to
submit the findings of the study to peer-reviewed journals
or academic conferences to be published.
Trial registration number ACTRN12616001549415; Preresults.

Strengths and limitations of this study
►► This is the first randomised controlled trial to inves-

tigate the combined effects of a multimodal exercise
programme with omega-3, vitamin D and protein
supplementation on cognition in older adults with
subjective memory impairments.
►► The exercise programme is structured, supervised
and delivered in a community, rather than a laboratory setting.
►► The study has an additional follow-up period to enable assessment of longer term cognitive changes
(over 12 months).
►► It was not feasible to examine the isolated effects of
the exercise programme and dietary supplement in
separate study arms.

Introduction
Globally, the population is ageing, and the
number of people living with dementia is
set to increase by at least 50% in the next 20
years.1 Delaying dementia onset by as little
as 6 months could reduce prevalence by 6%,
with a delay of 5 years predicted to decrease
prevalence by 44%.2 Therefore, strategies to
reduce dementia risk factors, delay dementia
onset and to slow the rate of neuropathology
are urgently needed to reduce the economic
and social burden of dementia and related
cognitive disorders.
Alzheimer’s disease (AD) is a form of
dementia characterised by progressive neurodegeneration, decline in memory and other
cognitive processes. Current pharmacological treatments at best reduce AD symptomatology and have not demonstrated efficacy
to delay dementia onset in those at high risk
of developing AD.3 Mechanisms contributing
to the neuropathology of AD are known to
include neuroinflammation, oxidative stress,
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Exercise, omega-3 fatty acids and vitamin D for cognitive
function
Exercise is a candidate to attenuate neuropathology and
enhance brain health throughout life via the regulation
of growth factors and neurotrophins such as insulin-like
growth-factor 1 (IGF-1), brain-derived neurotrophic
factor (BDNF) and vascular endothelial growth factor
that are involved in angiogenesis, synaptogenesis and
neurogenesis and the modulation of systemic inflammation.5 Exercise can positively influence cardiovascular
health and insulin resistance, which are pathways relevant
to cognitive decline.6 A large body of research has demonstrated that greater levels of physical activity are associated with slower rates of cognitive decline7 and a lower
risk of dementia.8 Furthermore, randomised controlled
trials (RCTs) have shown that even acute bouts of exercise
can provide small benefits to cognition.9 Findings from
recent meta-analyses have indicated that longer duration
exercise interventions can enhance cognition in healthy
p eople>50 years of age10 as well as individuals at risk of or
diagnosed with AD.11
While questions still remain regarding the optimal
mode and dose of exercise required for cognitive improvements,12 a recent systematic review and meta-analysis of
36 RCTs in community-dwelling adults, aged 50 years and
above,10 provided the recommendation that combined
aerobic and resistance exercise, at a moderate to high
intensity, as many days of the week as feasible, is suitable
to enhance cognitive function. Exercise interventions of
4–6 months’ duration that have used resistance or multimodal programmes, incorporating resistance training,
have indicated that, in older people, a frequency of
two sessions per week can benefit cognition.13–15 Importantly, cognitive benefits have been observed for resistance training when compared with ‘sham’ exercise or
stretching conditions designed not to impact heart rate
or aerobic capacity.13 14 16 The use of a control exercise
condition that is matched for social interaction, including
attention from the trainer delivering the programme, is
necessary to account for possible benefits to cognition
attributed to the social experience, rather than the exercise programme.
Accumulating evidence, largely from epidemiological
studies, suggests that various dietary factors alone and
in combination, particularly omega-3 fatty acids and
vitamin D, are strongly linked with cognitive decline
and dementia.17–20 Polyunsaturated fatty acids (PUFAs)
serve an essential role in the brain, regulating the function and structure of neurons, endothelial cells and glial
cells.21 The long-chain omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) also
modify neurotransmission, reduce neuroinflammation
and promote neuronal survival and neurogenesis.21 The
2

high intake of omega-6 fatty acids in the Western diet
(ie, from vegetable oil) causes an imbalance of omega3/6 fatty acids, resulting in lower than optimal levels of
DHA and EPA.22 23 A high intake of omega-6 fatty acids
has been suggested to adversely impact cognition by
depleting DHA, the omega-3 PUFA most prevalent in
the brain.24 In contrast, a low omega- 6/3 ratio has been
shown to predict better cognitive function in healthy
older people.25
Greater dietary intake of DHA (from consumption of
fish) has been linked to better cognitive outcomes in older
people26 and a 36% lower risk of AD across multiple observational studies.17 A dose–response meta-analysis showed
that an increment of 100 g per week of fish intake was
associated with an 11% lower risk of AD.17 In older people
with mild memory complaints (n=437) 900 mg/day of
DHA supplementation for 24 weeks improved episodic
memory and learning on computerised measures.27 Of
note, when compared with normative data, the improvements due to DHA supplementation on the verbal learning
test approximated a 7-year improvement, compared with
a 3.6-year improvement with placebo. Another study
conducted in 50 older people with mild cognitive impairment found that both EPA rich (1.67 g EPA+0.16 g DHA/
day) and DHA rich (1.55 g DHA+0.40 g EPA/day) supplements, taken daily for 6 months, improved depressive
symptoms, compared with an omega-6 rich supplement.28
In this study, only the DHA-rich supplement improved a
single cognitive domain as well as physical health. As not
all studies have yielded positive results regarding omega-3
fatty acid supplementation on cognitive function,29–31
dose and target population may be crucial factors.
An emerging role for vitamin D in the maintenance of
brain health and cognition is developing with reports that
serum 25-hydroxyvitamin D (25(OH)D) levels are lower
in those with impaired cognitive function and AD than
healthy controls18 32 and low vitamin D levels increase AD
risk 7 years later.33 Observational studies indicate that
inadequate vitamin D intake is linked to poorer cognitive
function34 and may increase the probability of cognitive
impairment by as much as 30%.35 Relatively few RCTs
have investigated the impact of vitamin D supplementation on cognition in older adults,35 although clinical trial
registries indicate a number of studies are underway. In
a recent 18-week study comparing high-dose vitamin D3
(4000 IU/day) to a low dose (400 IU/day) in 82 healthy
adults, the high-dose supplementation improved visuospatial memory but not other cognitive domains.36 As
even the low dose increased 25(OH)D concentrations
above 75 nmol/L, this may have impacted the ability to
detect cognitive changes dues to higher dose supplementation, as 75 nmol/L is the suggested optimum value to
exceed to reduce cognitive and brain dysfunction.37
Whether there is an additive effect of different nutrients with exercise in terms of benefits to brain health
is an important question. Research in rodents has indicated that DHA can enhance the effects of exercise on
BDNF-related synaptic plasticity,38 and vitamin D has
Macpherson H, et al. BMJ Open 2019;9:e024145. doi:10.1136/bmjopen-2018-024145
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mitochondrial and cerebrovascular dysfunction.4 Interventions that target such modifiable processes, while
promoting neuroplasticity and neuroprotection are
essential to combat cognitive decline and AD.
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Muscle mass and strength and cognitive function
The ageing process targets multiple systems of the
body, leaving older individuals vulnerable to deterioration of brain, vascular and musculoskeletal systems. A
progressive loss of muscle mass, strength and function,
termed as sarcopenia, occurs with ageing. After the age
of 40–50 years, there is a progressive loss of muscle mass
in the magnitude of 1%–2% per year.40 Sarcopenia is a
growing public health concern, increasing the risk of
low trauma fracture, disability, morbidity and reducing
quality of life in older people.40
Low muscle strength has been linked to lower global
cognitive performance41 and a higher risk of cognitive impairment.42 Greater frailty has been associated
with increased cognitive decline in patients with AD.43
A recent investigation using data derived from the UK
Biobank identified a significant relationship between grip
strength and multiple cognitive domains in over 475 000
individuals from the general population.44 While these
findings emphasise the connection between muscular
Macpherson H, et al. BMJ Open 2019;9:e024145. doi:10.1136/bmjopen-2018-024145

strength and brain health, more research is needed to
determine whether increasing muscle mass and strength
can enhance cognitive function. Results from the Study
of Mental and Resistance Training (SMART) trial showed
that strength improvements due to 6 months of high
intensity resistance training were associated with improvements to cognitive function in older people with mild
cognitive impairment.45
Combining dietary protein supplementation with resistance training exercise has been proposed as a strategy
to offset muscle decline in older people.46 A 16-week
RCT conducted in older women found that increasing
lean red meat intake, combined with twice weekly resistance training, increased lean tissue mass and muscle
strength compared with resistance training coupled with
a high carbohydrate diet.47 A recent meta-analysis has
confirmed that dietary protein can augment the effects of
resistance training exercise on muscle mass and strength,
although the findings indicate that resistance training is
the more potent stimulus for increasing muscle strength
than protein intake.48 Protein dose may be an important
consideration, with an RCT in men aged >70 years having
demonstrated that providing double the recommended
daily allowance (RDA) of protein (1.6 g protein/kg/day),
compared with the RDA, for 10 weeks provided benefits to lean body mass and knee extension peak power.49
These findings are consistent with the premise that
older adults need a higher intake of protein to increase
muscle protein synthesis.46 With regards to the impact of
combining exercise with protein on cognitive function,
there is some evidence that the combination of 30 g daily
protein supplementation and resistance training exercise for 6 months enhanced processing speed in frail and
prefrail elderly.50 While a consistent benefit of protein
supplementation for cognition has not been established,
it has been proposed that amino acids such as tyrosine
and tryptophan may be capable of modulating cognitive
function.51
Objective
It is hypothesised that a multifaceted approach combining
exercise with dietary modification involving omega-3 fatty
acids, vitamin D and protein may offer cognitive benefits, relative to the control condition, as they will target
complementary pathways related to neuroinflammation,
neuroprotection and neuroplasticity.5 21 35
The primary aim of this study is to investigate the efficacy
of a 6-month multifaceted intervention, incorporating an
exercise programme with omega-3 fatty acid, vitamin D
and protein supplementation on cognitive function in
older people with subjective memory complaints. The
secondary aims are to: (1) determine if any beneficial
effects of this intervention on cognitive function are mediated through increases in muscle strength or mass, (2)
explore the impact of the intervention on other aspects
of psychological and physical health and (3) evaluate the
longer term residual effects (6 months after cessation of
the intervention) on cognition.
3
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the potential to contribute to these actions through the
regulation of neurotrophins BDNF, glial cell line-derived
neurotrophic factor, nerve growth factor and IGF-1.35 As
a neuroprotective agent, vitamin D may target specific
AD pathology, attenuating amyloid-beta (Aβ) accumulation by stimulating the phagocytosis of the Aβ peptide
and inducing cytokines and macrophages to increase Aβ
clearance.35 Exercise and DHA exert potent anti-inflammatory effects5 21 and vitamin D may further attenuate
inflammation-induced degeneration of neurons by inhibiting the production of tumour necrosis factor-α, interleukin-6 and nitric oxide, preventing lipid peroxidation
and reversing mitochondrial dysfunction under conditions of heightened oxidative stress.35
The cognitive effects of omega-3 fatty acids combined
with a more complex lifestyle intervention, incorporating
exercise, have recently been examined in the large 3-year
RCT Multidomain Alzheimer Prevention Trial (MAPT).
This study examined the impact of omega-3 fatty acid
supplementation (800 mg/day DHA +250 mg/day EPA)
and a multidomain intervention (cognitive training,
physical activity and nutrition advice and three preventative consultations), alone or in combination, compared
with placebo on cognitive function in 1680 community-dwelling, non-demented adults aged 70+ years.39 The
combination of omega-3 fatty acids and the multidomain
intervention enhanced cognitive performance on a
secondary measure of cognitive function and in subgroup
analyses of those with an increased dementia risk score,
but no benefits were found for the primary cognitive
endpoints. The absence of an effect on the primary
outcome for the multidomain intervention may have
been influenced by the design of the exercise component
that was limited to generic physical activity advice to be
more active (eg, aim to walk 30 min per day) and did not
include a structured programme designed to enhance
physical function.

Open access

Participants and screening
Participants will be included into the study based on the
following criteria: (1) presence of subjective memory
complaints, defined as a positive response to the question ‘do you feel like your memory is becoming worse?’
and a score >17 on the Montreal Cognitive Assessment
(MoCA), (2) community dwelling and aged 60–85 years,
(3) fluent in written and spoken English and (4) with
normal or corrected to normal vision and hearing.
To minimise extraneous causes of cognitive impairment, participants will be excluded based on the
following: (1) diagnosis of AD or other dementia and
Parkinson’s disease; (2) history of brain damage including
significant head trauma, stroke or serious neurological
disorder, including loss of consciousness >24 hours; (3)
clinical diagnosis of psychiatric disorder likely to affect
cognition, including current clinical diagnosis of depression, commencement of anti-anxiety or antidepressant
medication within the past 6 months, score of >5 on the
short Geriatric Depression Scale; (4) or alcohol or drug
dependency within the last 2 years. Exclusion criteria
relevant to the study intervention, supplement and/or
exercise programme, will include: (5) existing diagnosed
gastrointestinal disorders likely to impact absorption of
fatty acids (eg, coeliac disease); (6) known allergy to fish
or any other component in the dietary supplement; (7)
type two diabetes; (8) body mass index >40; (9) health
conditions that contraindicate exercise or insufficient
mobility to exercise; (10) participating in progressive
resistance training >1 week or more >150 min per week
of moderate intensity physical activity; (11) current
smokers; (12) oily fish consumption (≥1/week); (13)
4

daily use of omega-3 rich supplement >500 mg or vitamin
D supplements >500 IU within the past 12 weeks; (14) use
of cholinesterase inhibitors, benzodiazepines, antipsychotics or high-dose antidepressants (judged by medical
advisor), use of warfarin or high dose blood thinners,
resistant hypertension defined as the use of more than
three antihypertensive agents and medications contraindicated for use with omega-3 fatty acids, vitamin D or
protein. Any uncertainty or discrepancies about participants’ clinical history will be resolved by consulting with a
physician familiar with the study (investigator SM).
Participants will be recruited from within the local
community in Melbourne (Australia) and surrounding
areas via newspaper advertisements, community presentations, social media and community notice boards. Participants will be provided with the exercise programme free
of charge as an incentive to participate in the trial.
Randomisation
Participants will be randomly allocated to one of the two
parallel groups using a simple randomisation computer
generated random sampling set, with an allocation ratio
of 1:1. Randomisation will be stratified for gender and age,
separated into three categories of 60–69.9 years, 70–79.9
and 80–85.9 years. Randomisation will be conducted by
personnel not otherwise involved in the trial. Participant
group allocation will be provided in an opaque envelope
to the researcher involved in assigning participants to the
intervention, on completion of the baseline appointment.
The researcher who assigns participants to the intervention will distribute the study treatment and provide information about the assigned exercise programme. This
researcher will no longer be blinded from this point.
Blinding
Both the active supplement and the placebo will be packaged in non-transparent sachets. All researchers involved
in outcome assessments will be blinded to participant
group allocation, with the exception of the 6-month
dual-energy X-ray absorptiometry (DXA) scan, which
may be conducted by an unblinded researcher due to
limited qualified personnel. All DXA analyses will be
carried out by a blinded researcher. During the intervention period, only unblinded researchers will be in contact
with participants enrolled in the trial. In order to maintain a double-blind study design, participants will not be
informed that all individuals assigned to the multimodal
exercise programme will also receive the supplement
drink containing omega-3, vitamin D and protein, nor
that all participants assigned to the stretching/flexibility
condition will also receive the placebo. The purpose of
concealment will be explained when all participants have
completed the trial. Exercise trainers delivering the exercise programme will not be informed that participants in
the multimodal exercise programme are receiving the
active supplements or those in the stretching group are
receiving the placebo. All data analysis will be completed
by personnel who are blinded to the intervention
Macpherson H, et al. BMJ Open 2019;9:e024145. doi:10.1136/bmjopen-2018-024145
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Methods/design
Study design
This is a 12-month, community-based, parallel group,
randomised, double-blind, placebo-controlled trial
involving a 6-month supervised and structured intervention, followed by an additional 6-month follow-up
to evaluate any long-term residual effects. A total of 148
individuals with subjective memory impairment (SMI)
aged 60–85 years will be randomised to: (1) a supervised
multimodal exercise programme involving progressive
resistance training and aerobic exercise, combined with
omega-3 fatty acid, vitamin D and protein supplementation or (2) a stretching/flexibility exercise programme
and placebo supplements. During the 6-month postintervention follow-up, participants will no longer be provided
with the exercise programmes or supplements but will be
encouraged to continue to exercise and follow a healthy
diet. This study protocol is reported in accordance with
the Standard Protocol Items: Recommendations for Interventional Trials statement,52 and results will be reported
in line with the Consolidated Standards of Reporting
Trials (CONSORT) statement53 and the CONSORT
statement for non-pharmacological interventions.54 The
study was prospectively registered on the Australian New
Zealand Clinical Trials Registry on 10 November  2016.

Open access

Intervention
Multimodal exercise programme plus omega-3, vitamin D and
protein supplement drink
Exercise intervention: participants will take part in a
6-month group community-based programme designed
by an exercise physiologist, conducted within local health
and fitness centres located in Melbourne, Australia.
Participants will attend 2×1 hour weekly supervised exercise sessions for 6 months at a health and fitness centre
in close proximity to their home. Exercise classes will
be exclusive to PONDER study participants and will not
exceed 10 participants. Exercise sessions will be supervised
by a dedicated, accredited exercise trainer. Each exercise
session will involve a 5–10 min group warm up, 15 min of
aerobic exercise followed by approximately 30–40 min of
progressive resistance training concluding with a 5 min
cool down. The aerobic exercises will be rotated rather
than progressed. In line with current recommendations
to enhance cognition,5 the progressive resistance training
will consist of two sets of 8–12 repetitions, at a weight that

cannot be lifted for more than these number of repetitions, at a rating of perceived exertion of 5–8 (‘hard to
very-hard’) on the 10-point scale.55 This will be completed
for eight resistance exercises involving dynamic concentric and eccentric contractions targeting all the major
muscle groups and with an emphasis on weekly progressive overload (increments of 2%–10%). Details of the
multimodal programme are shown in table 1.
Supplement: the study treatment will be a vanilla-flavoured daily supplement drink containing 5 g of
omega-3 powder (18% EPA, 12% DHA equivalent to
900 mg EPA and 600 mg DHA), vitamin D3 1000 IU and
25 g of whey protein concentrate (WPC) 80. The total
of 1.5 g omega-3 fatty acids is a physiologically relevant
dose (equal to half portion of farmed Atlantic salmon or
a full portion of fresh or tinned wild Atlantic salmon).56
The aim of 1000 IU/day vitamin D3 treatment is to raise
serum 25(OH)D concentrations to at least 50–60 nmol/L,
in line with current Australian recommendations.57 When
combined with resistance training, 20 g of whey protein
isolate has been demonstrated to increase muscle protein
synthesis in older people58; therefore, 25 g of WPC was
selected to provide a comparable dose of protein. Each
drink will provide approximately 590 kJ of energy, 2 g
of lactose, 6 g of fat and 20 g of protein. The supplement will be provided in powder form to be mixed with
200 mL water. The treatments have been developed by
Omniblend Australia. Participants will be instructed to

Table 1 Details of the exercise programmes
Frequency

Multimodal exercise
2× per week.

Intensity

RPE rating of 5–8 (hard to very hard).

Duration

60min.

Warm up

5min group-based warm up including balance and mobility exercises.

Aerobic

15 min aerobic training rotating exercises: treadmill, bike, stepper, rower, X-trainer/elliptical trainer and so on.

Resistance

30–40 min resistance training: eight exercises (six resistance, two core), two sets, 8–12 reps targeting all
the major muscle groups and with an emphasis on weekly progressive overload (increments of 2%–10 %).
Resistance exercises may include: squats / leg press, lat pulldown, calf raises, chest press/seated row,
modified plank and so on.

Cool down

5–10min cool down: relaxation type exercises incorporating stretching.
Stretching and flexibility.

Frequency

2× per week.

Intensity

Light

Duration

50–60 min.

Warm up

5 min light walking/marching, range of motion exercises.

Aerobic

Nil.

Resistance

Nil.

Flexibility

35–40 min variety of light stretching/flexibility exercise and light resistance band exercises that will not
increase strength.
5–10 min cool down: relaxation type exercises.

Cool down

RPE, rating of perceived exertion.

Macpherson H, et al. BMJ Open 2019;9:e024145. doi:10.1136/bmjopen-2018-024145
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assignment. Participants will be unblinded after the
12-month assessment.
The codes will only be broken in an emergency, such
as a severe adverse event that requires knowledge of
the treatment being taken in order to manage a participant’s condition. The principal investigator and ethics
committee will be informed within 24 hours of the codebreak envelope being opened.

Open access

Control group (stretching/flexibility programme+placebo drink)
Exercise: participants will complete a 6-month group
community-based stretching/flexibility programme
designed by an exercise physiologist within local health
and fitness centres. Participants will attend 2×1 hour
weekly supervised exercise sessions for 6 months. Groups
will be exclusive to study participants. The exercise
programme will involve stretching and is designed not
to influence heart rate, strength or aerobic capacity but
to provide a similar level of social contact and attention
from a dedicated exercise trainer at each centre. Details
of the stretching/flexibility programme are shown in
table 1.
Supplement: the placebo drink will be vanilla flavoured
and matched for appearance and caloric content and will
contain 16 g whole milk powder and 15 g maltodextrin.
Each drink will provide approximately 590 kJ of energy.
Compliance
Compliance to the exercise programmes will be assessed
using attendance records and for the multimodal
group, monthly exercise cards collected from the exercise trainers. Each exercise card contains information
regarding sessions attended, exercises completed, set,
repetitions, time and training intensity. A compliance
calendar showing each month will be provided to assess
supplement compliance. Participants will mark off each
day the supplement is consumed and record any reasons
for variations (ie, missed supplement or taken later in
the day). Participants who are non-compliant with the
intervention will still be requested to attend all follow-up
appointments.
Adverse events
Any adverse events potentially or confirmed to be associated, with the exercise programme will be recorded
on the exercise cards provided to the exercise trainers.
The supplement calendar will be used to record adverse
events potentially due to the supplement. Any health-related unfavourable or unintended medical occurrence
(eg, sign, symptom, syndrome and illness), deemed to be
relevant to the study, that develops or worsens during the
trial will be classed as an adverse event. All adverse events
will be assessed for seriousness, severity, causality and
expected outcome by the researchers. There will be no
formal data monitoring committee, due to the size of the
study and the single site; however, all data will be reviewed
by the research team at regular intervals throughout the
study.
6

Figure 1 Flow diagram: participant recruitment and
screening flow chart.

Sample size calculation
To date, no studies have investigated the cognitive effects
of the specific intervention combination examined in
the current study. For this reason, the anticipated effect
size is largely based on findings derived from the exercise literature. Exercise exerts an average 0.5 SD effect
size (equating to a medium effect size) on executive
function.5 A recent meta-analysis has indicated that multimodal exercise interventions of at least 4 weeks’ duration
have a positive effect on cognition in the order of a 0.33
effect size, in people over the age of 50 years.10 Based on
these figures, we anticipate at least a medium effect size
(f=0.25). Allowing for 15% attrition rate, a sample of 148
participants, with 74 individuals assigned to each study
arm, will provide a power level of 0.8 at the 5% probability level.
Procedure
Participants will attend a total of four visits to Deakin
University in Melbourne to undergo study assessments
(see figure 1). All participants will be requested to abstain
from alcohol for 24 hours prior to study visits. No caffeine
is to be consumed 2 hours prior to study visits, and participants will consume the same food and drink at the baseline (V1) and 6-month (V2) visits. Baseline and 6-month
visits will be held at the approximate same time of day
(within 2 hours).
►► Prescreening: all participants will undergo telephone
screening.
►► Screening (V0): potential participants who meet the
prescreening study criteria will attend a face-to-face
session with a researcher to provide written informed
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consume the supplement immediately before breakfast,
except on days involving the exercise programme, when
they will be requested to consume the supplement 1–2
hours after completing the session. To reduce the likelihood of any gastrointestinal side effects, participants will
be instructed to consume only half the supplement dose
for the first 7 days of the intervention.
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►►

►►

►►

Primary outcome
Change in global cognitive function derived from the
CogState computerised battery and the Trail Making Test
after 6 months.
Secondary outcomes
Changes in cognitive function for the six individual
measures and the composite scores of working memory/
learning and attention/psychomotor function assessed
using the CogState battery, the Trail Making Test, the
MoCA after 6 months and 12 months, and changes in
mood, health-related quality of life, strength, physical
function, body composition, cardiovascular health and
sleep quality after 6 months. A list of outcomes and time
points are shown in table 2.
Screening measures
The self-administered 15-item Short Form Geriatric
Depression Scale (GDS)59 will be used to screen for the
presence of depression at V0. Scores greater than 5 potentially indicate depression and those who score >5 will not
be eligible for the study. The interviewer administered
MoCA60 will be used to screen for the possible presence
Macpherson H, et al. BMJ Open 2019;9:e024145. doi:10.1136/bmjopen-2018-024145

of dementia. The MoCA is scored out of 30 and assesses
short-term memory, visuospatial ability, executive function, verbal fluency, attention and working memory and
orientation to time and place and is summed to create
a global measure of cognition. Participants require
a score >17 to be eligible for the study. The MoCA has
been shown to have 90% sensitivity and 87% specificity
for detecting MCI (n=94) and 100% and 87%, respectively, for detecting early AD.60 The MOCA will be used
for screening purposes at V0 and repeated as a secondary
outcome after 6 months (V2) and 12 months (V3).
Primary outcome measures
Cognitive assessments
The Cogstate Computerised Battery (
www.
cogstate.
com) will be used to assess cognition for six cognitive
tasks, which will form the basis for two composite scores
(working memory/learning and attention/psychomotor
function) and a measure of global cognitive function,
which will be the primary outcome. The individual
cognitive tasks include the Detection Task (reaction time
task measuring psychomotor function), the Identification
Task (choice reaction time task measuring visual attention), the One Card Learning Task (visual recognition
memory and attention) and the One-Back Task (working
memory and attention). For all tasks, speed (reaction
time in milliseconds) and accuracy (number of correct
responses made) will be recorded. The fifth task is the
Groton Maze Task, which assesses executive function and
is calculated based on the number of errors. The final
task is the International Shopping List (verbal learning and
memory), which is scored using accuracy, calculated by
summing correct responses. Individual raw scores for
each task will be transformed into a z-score using the
mean and SD of the total sample in the study. Composite
scores for working memory/learning will be calculated by
averaging the standardised scores (z-score) for the One
Card Learning and One-Back Tasks, and the attention/
psychomotor function composite will be calculated by
averaging the z-scores for the Detection and Identification Tasks. Global cognitive function will be derived as
the average z-scores from all six tests, which higher scores
indicating better performance. The CogState computerised tasks are specifically designed for repeated administration over short time periods and have been validated
in older adults.61–63 Practice or fatigue effects are minimal
for these tasks, making them suitable for detecting subtle
cognitive changes.61–63 To further minimise practice
effects, the entire battery will be practised at V0.
The Trail Making Test64 65 Part A (visuoperceptual
ability) involves drawing lines to connect numbered
dots in ascending numerical order as quickly as possible
while still maintaining accuracy. Part B (working memory
and task-switching ability) involves connecting dots in
ascending order, alternating between numbers and letters
as quickly as possible. The score is the number of seconds
taken to complete each part of the test. The score from
Part B minus Part A provides an indication of executive
7
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►►

consent and undergo screening for inclusion/exclusion criteria. Eligible individuals will undergo familiarisation of core study measures and will be provided
with a physical activity monitor and pathology collection requests to complete blood collection prior to
V1. Participants requiring medical approval must
obtain this prior to baseline.
Baseline (V1): to be conducted within 4 weeks of the V0
screening visit. During V1, cognitive assessments will
be carried out first, followed by cardiovascular measures, anthropometry, DXA, functional measures and
questionnaires. On completion of V1, participants
will be allocated to either the intervention group or
control group and provided with the supplement and
details of the relevant gym programme. Participants
are requested not to commence additional omega-3
or vitamin supplementation during the trial or to take
part in more than one additional structured exercise
class per week.
Intervention period: an unblinded study member will
remain in contact with participants via telephone and
face-to-face visits at the gyms and will collect exercise
cards, including adverse event logs and supplement
compliance logs. Possible adverse events, gym non-attendance and supplement non-compliance will be
followed up by telephone by an unblinded researcher.
6 month follow-up (V2): participants will repeat physical
activity monitoring and blood collection within the
week prior to V2. All measures from baseline will be
repeated along with the MaCA.
12-month follow-up (V3): due to funding constraints,
only cognitive assessments including the Cogstate,
Trail Making Test and MoCA and study questionnaires
will be completed at V3.
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Outcome measures

Data collection method

Visit 0:
practice

Visit 1:
baseline

Visit 2:
6 month

Visit 3:
12 month

Primary outcome
 
Cognitive function

Cogstate Computerised Battery

Practice

X

X

X

Trail Making Test

Practice

X

X

X

Montreal Cognitive Assessment

X

X

X

NART-R IQ

X
X

X

X

X

X

Hand grip strength

X

X

Four Metre Walk Test

X

X

Four-Square Step Test

X

X

30 s Sit-to-Stand Test

X

X

Timed Up and Go Test

X

X

Depression Anxiety Stress Scale

X

X

X

 
Quality of life

Short-form (SF)-36 version 2

X

X

X

 
Sleep

Pittsburg Sleep Quality Index

X

X

X

 
Personality

Short NEO-Personality Inventory

 
Demographics/lifestyle

Lifestyle Questionnaire

X

X

X

 
Anthropometry

Body mass index

X

X

Hip, waist and neck circumference

X

X

DXA (total body and regional)

X

X

Additional outcomes
Cognitive function

Cognitive Function Instrument
 
Muscle strength
 
Physical function

 
Mood

 
Body composition

3RM Knee extension

Practice

Short Geriatric Depression Scale

X

X

 
Cardiovascular function Resting blood pressure
 

Central arterial pressure, pulse wave velocity and
arterial stiffness

X

X

 
Diet

ASA-24 Dietary Assessment Tool

X

X

PUFA Questionnaire

X

X

 
Habitual
physical activity

CHAMPS Survey

X

X

X

7-day physical activity (Actigraph)

X

X

X

Cholesterol and HsCRP

X

X

Omega-3 fatty acids and vitamin D
Apolipoprotein E e4 status

X
X

X

 
Biomarkers

X

3RM, three repetition maximum; ASA-24, Automated Self-Administered 24 hours; CHAMPS, Community Healthy Activities Model Program for
Seniors; DXA, dual-energy X-ray absorptiometry; HsCRP, high-sensitity C reactive protein; NART-R IQ, National Adult Reading Test Revised
IQ; PUFA, polyunsaturated fatty acids.

function65 and will be considered the primary outcome
generated from the Trail Making test. The Trail Making
Test has test–retest reliability ranging from 0.74 to 0.85.66
To minimise practise effects, the Trail Making Test will be
practised at V0.
Secondary outcome measures
Mood, quality of life and sleep
The 21-item Depression, Anxiety and Stress Scale
(DASS)67 will be used to assess mood. The DASS consists
of three subfactors that yield subscores for each domain:
8

depression, anxiety and stress. Higher total scores indicate a higher degree of mood dysfunction.
The self-administered Short Form 36 version 2 (SF-36
v2) questionnaire will be used to measure health-related
quality of life.68 The SF-36 covers the domains of physical
functioning, role-physical, bodily pain, general health,
vitality, social functioning, role-emotional and mental
health. The current study will report Australian normbased scores using previously published guidelines69 to
provide each domain score a standardised mean of 50
Macpherson H, et al. BMJ Open 2019;9:e024145. doi:10.1136/bmjopen-2018-024145
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Table 2 Outcome measures and relevant data collection time points
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Muscle strength
Lower body muscle strength will be determined by the
Keiser bilateral knee extension machine (Keiser Corporation, Fresno, California, USA), using a standard
three repetition maximum protocol (see ref 71). Participants will warm up with 8 repetitions at 3 kg. The weight
will be increased progressively to participant’s estimated
three repetition maximum (kg). After a 2 min rest, resistance will be increased (or decreased) until only three
repetitions in good form can be completed.
Bilateral maximal isometric grip strength will be
measured using a hand-held dynamometer (Jamar dynamometer, Asimov Engineering Co, Los Angeles, California, USA). In a seated position, with elbow flexed at
90°, forearm neutral and hand slightly extended, participants will be instructed to squeeze the hand grip as tightly
as possible and release for three trials with a 1 min rest
between trials. After a practise trial, the maximal grip
strength (kg) of each hand will be recorded. The test
is performed by both the dominant and non-dominant
limbs.
Physical function
All functional tests will be preceded by a practise trial.
The 4 m walk test will be used to assess gait speed. Participants walk in a straight line at their normal walking speed
across four metres with speed recorded using timing gates
(Swift Speedlink Performance Equipment systems). The
outcome will be the fastest time measured in seconds (to
the nearest millisecond) from two trials.
The Four-Square Step Test (FSST) will be used to assess
dynamic standing balance and stepping speed in four
different directions.72 The FSST is completed first in a
clockwise and then counter-clockwise direction. Participants will complete two test trials, and the outcome will
be the fastest time (in seconds) taken to complete the
sequence.
The Timed Up and Go Test measures dynamic balance
during three commonly performed functional activities:
standing up from and sitting down in a chair, walking and
turning.73 Participants are required to stand up from a
chair, walk as quickly as possible around a cone (marking
3 m), turn and walk back to the chair and sit down. The
outcome will be the time (in seconds) to complete the
sequence.
Macpherson H, et al. BMJ Open 2019;9:e024145. doi:10.1136/bmjopen-2018-024145

The 30 s Sit-to-Stand Test74 will be used to assess lower
extremity muscle strength and power. Starting from a
seated position in a chair, chair measuring 45 cm from the
ground, with arms folded across the chest, participants
stand fully upright and then return to the seated position as many times as possible in 30 s. The outcome is the
number of sit-to-stands completed in 30 s.
Anthropometrics and body composition
Height will be measured in centimetres using a stadiometer fixed to the wall, and weight will be measured in
kilograms using calibrated scales with standardised protocols. Body mass index (BMI) will be calculated as weight
(kg)/height (m2). Waist and hip circumference will be
measured in centimetres using the WHO protocol.75
Waist-to-hip ratio will be calculated by dividing the waist
circumference measurement by the hip circumference. Neck circumference will be measured around the
midpoint of the participant’s neck, between the midcervical spine and mid anterior neck. All measures will be
taken twice and the average value used as the outcome.
Dual-energy X-ray Absorptiometry (DXA) will be used
to assess body composition (fat, lean and bone) (Lunar
iDXA, version Encore 16.2, GE Healthcare Medicine,
Wisconsin, USA). Total body lean mass, fat mass and
percentage body fat will be determined from the total a
regional (arm and legs) body. Standardised procedures
(2015 ISCD official positions) for participant positioning
and scan analysis will be used for all scans (https://www.
iscd.org/official-positions/2015-iscd-official-positions-
adult/). During each visit participants will be scanned
in a hospital gown and instructed to remove all metal
objects. All scans for all participants will be performed by
the same operator on the same scanner following daily
quality assurance and control monitoring.
Cardiovascular health
Seated blood pressure will be assessed using an ambulatory blood pressure monitor. The blood pressure cuff
will be fixed to the left arm following a 5 min period of
seated rest. Four consecutive measurements will be taken
at 1 min intervals and the average of the final three readings will be used as the outcome.
The SphygmoCor XCEL (AtCor Medical PTY) will
be used to measure central arterial pressure waveform,
pulse wave velocity (PWV) and arterial stiffness. Pulse
wave analysis (PWA) will be measured after 5 min of quiet
supine rest with the cuff attached to the left arm held in
a straight position. Measures will be taken twice and the
average value used at the outcome. To conduct carotid-femoral PWV, a cuff will be placed around the femoral
artery to capture the femoral waveform, and a tonometer
will capture the carotid waveform. The distance between
the carotid and femoral arteries will be measured, and the
velocity automatically calculated by dividing the distance
by the pulse transit time. Measures will be taken twice,
with a third measure completed if the difference between
9
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and a SD of 10. Separate quality of life summary scores
will be calculated for the physical component and the
mental component.
The self-administered 19-item Pittsburgh Sleep Quality
Index (PSQI) will be used to measure sleep quality and
disturbance over a 4-week period.70 The scale is composed
of items that generate seven subscores: subjective sleep
quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbance, use of sleep medications and
daytime dysfunction. Both the total score and subscores
will be outcomes for this measure.

Open access
25(OH)D will be used to determine changes in vitamin D
levels due to the supplement.

Demographic variables and potential covariates
Demographic and lifestyle information will be collected
on participant’s ethnic and educational background,
employment history/status, medical history, history of
falls and fractures, family history of osteoporosis, current
medication and dietary supplement use, alcohol intake,
weekly television viewing and sitting time and sun exposure habits.

Apolipoprotein E (ApoE) status
ApoE is involved in lipid homeostasis, particularly in the
determination of the levels of LDL and HDL cholesterol,
which are directly and inversely correlated with risk for
cardiovascular disease respectively.83 Carriers of the ApoE
e4 allele have increased coronary risk,84 and e4 carriers
also have a higher risk of developing late onset AD.85
Although e4 carriers may experience a similar benefit
from lifestyle based interventions, their rate of cognitive
change may be greater than in non-carriers.86 ApoE status
will be assessed at baseline (V1), DNA will be extracted
from venous whole blood samples using commercially
available kits.

Cognitive and psychological factors
The National Adult Reading Test-Revised (NART-R)
will be used to estimate IQ.76 The NART-R is suitable to
assess premorbid intellectual functioning in the presence of cognitive impairment.77 The number of errors in
pronunciation will be converted to an estimate of FullScale IQ score. The Cognitive Function Instrument78 is a
self-report measure of 14 items that probe experiences of
memory decline over the past year. This measure will be
used to provide greater detail regarding subjective cognitive complaints and has been demonstrated to correlate
with objective cognitive decline.79 The short 60-item NEO
Personality Inventory will be used to assess the five major
personality domains of extraversion, agreeableness,
conscientiousness, neuroticism and openness to experience80 as personality characteristics may contribute to
subjective cognitive complaints.81
Blood biomarkers
Within 7 days prior to baseline (V1) and 6 months (V2),
participants will attend a commercial pathology clinic
collection centre where a fasted, morning (08:00–10:00)
venous blood sample will be collected. Blood samples
will be separated into serum/plasma and red blood
cells by low speed centrifugation (3000 rpm, 4°C for
10 min). The following samples will be sent to a central
pathology laboratory accredited by the National Association of Testing Authorities Royal College of Pathologists
Australasia: serum total cholesterol, high-density lipoprotein (HDL)-cholesterol and triglycerides will be analysed
using an enzymatic colorimetric method (Roche Diagnostics, Mannheim). Low-density lipoprotein (LDL)-cholesterol will be calculated using Friedewald’s formula.
Serum creatinine, urea, albumin, calcium, phosphorus,
sodium, potassium and phosphorus will be analysed using
standardised techniques. Additional packed red blood
cells, plasma and serum samples will be stored until analysed. Samples will be stored in a −70°C freezer prior to
being transferred to Deakin University, where samples
will be stored at –80°C until the study is complete. Erythrocyte levels of omega-3 PUFAs will be extracted based on
LePage and Roy method.82 The extracted fatty acids will
be separated by gas chromatography, identified by the
comparison with known fatty acid standards and quantified by comparison to the internal standard (21:0). Serum
10

Physical activity
The Community Healthy Activities Model Program
for Seniors (CHAMPS) physical activity questionnaire
will be used to calculate total leisure and recreational
physical activity time. This measure has been designed
for use in older adults and is reliable, valid and sensitive to change.87Individuals will document their weekly
frequency and duration of participation in a ‘typical
week’ of the preceding 4 weeks. Outcomes will be hours
per week, and estimated kilojoules per week, spent in
moderate to high intensity activities.
To obtain an objective measure of physical activity,
participants will be provided with an Actigraph monitor
to wear for a period of up to 7 days on three occasions.
The Actigraph is a small lightweight monitor that will be
worn on the right hip to measure quantity and intensity
of physical activity. Monitors will be removed for sleep.
Participants will complete a log of their activity including
sleep hours to aid in interpretation of this data. Physical
activity information will be collected for the 7 days prior
to V1, V2 and V3 assessments. Time spent in sedentary,
light, moderate and vigorous activity will be calculated.
Diet
The Automated Self-Administered 24 hours (ASA24)
Australia Dietary Assessment Tool (https://
epi.
grants.
cancer.gov/asa24/) developed by the National Cancer
Institute will be used as a 24-hour dietary recall. The
ASA24 is completed online; however, it will be conducted
over the phone with a researcher if participants do not
have computer and internet access. The ASA24 allows
respondents to report foods and drinks and amounts
consumed by browsing a food category or searching from
a list of food and drink terms derived from the 2007–2008
National Health and Nutrition Examination Survey. The
ASA-24 provides a breakdown of macronutrients and
energy, vitamins, minerals, carotenoids, fats, cholesterol
and fatty acids.
A validated online questionnaire will be used to assess
dietary PUFA intake. The PUFA questionnaire is a simple
non-invasive method that estimates the intakes of omega-3
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the PWV readings is >0.5 m/s. The average value will be
used at the outcome.
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Statistical analysis
Data will be analysed using SPSS V.25 and STATA V.15
applying standard statistical thresholds (p<0.05),
corrected for multiple comparisons where appropriate.
There will be no interim data analysis. All data will be
checked for normality prior to analysis. Data will be
analysed based on an intention-to-treat approach using
linear mixed models with random effects. Changes in
the primary outcomes (CogState global cognitive function and Trail making test of executive function), and all
secondary outcomes will be expressed as the absolute or
percentage difference for the change between the intervention group and control group after 6 months or 12
months, as appropriate. For the cognitive outcomes, the
results will be analysed adjusted for age, gender and years
of education (model 1) as well as baseline MoCA score
and ApoE status (model 2). Per-protocol analysis will be
used to determine the effectiveness of the intervention
among participants who are considered to be compliant
with the intervention. Participants who attended 67%
(two-thirds) of exercise sessions and consumed 80% of
the allocated supplement will be classified as adherent
for the purpose of completer analysis. All data will be
presented as mean±SD or 95% CIs.
Ethical approval, data management and dissemination plan
The current protocol is based on version 4, April 2017.
The first participants were enrolled into the study on
4 April 2017. In line with the ethical approval for this
study, all data will be de-identified and stored in a locked
filing cabinet or on a secure data drive at Deakin University. Only members of the research team will have access
to the data. Only study investigators will have access to
the final data set. Any changes to the trial protocol will
be reported to Deakin University Human Research Ethics
Committee and updated on the clinical trial registry. On
completion of the trial, participants will receive a report
outlining major study findings. They may also request
pathology results. Study investigators will disseminate
group results to the public in the form of journal articles, conference presentations, seminars and community
presentations.
Patient and public involvement
Participants were not explicitly involved in the development of the trial. Feedback will be sought from all
participants at the end of the study to assess burden of
Macpherson H, et al. BMJ Open 2019;9:e024145. doi:10.1136/bmjopen-2018-024145

intervention and to help develop future trials. Participants will receive individual result summaries of key
measures and a summary of the overall study findings.
Discussion
Given that dementia is among one of the major causes
of disability and death worldwide,89 interventions that
prevent cognitive decline and delay the onset of dementia
and related disorders are urgently needed. This study will
be the first to evaluate whether a multifaceted intervention
comprising of exercise combined with omega-3, vitamin
D and protein supplementation can improve cognitive
function in older adults at risk of cognitive decline and
provide information about potential underlying mechanisms. This study will evaluate the longer-term cognitive
impact of the multifaceted intervention.
Age-related impairments to cognitive and physical function are multifactorial; therefore, multidomain interventions that target multiple risk factors are needed to address
a wider range of mechanisms involved in cognitive and
functional decline. Promising results have been obtained
from the large-scale, 2-year Finnish Geriatric Intervention
Study to Prevent Cognitive Impairment and Disability
(FINGER) trial, which examined the impact of a multidomain intervention on cognitive function in 1260 older
adults aged 60–77 years, selected on the basis of elevated
risk for dementia.90 The study intervention included four
components including personalised and group dietary
recommendations, an individually tailored exercise
programme targeting progressive muscle strength and
aerobic exercise, group and web-based cognitive training
and management of metabolic and vascular risk factors
compared with regular health advice. The results of this
study demonstrated a significant benefit of the multidomain intervention to a composite cognitive score,
a processing speed and executive function composite
score, with improved or maintained cognitive function
from 25% to 150% better than the control group. The
only cognitive domain not to demonstrate an improvement was memory. These findings are important as they
suggest that making multiple lifestyle modifications can,
in turn, modify cognition.
While the results of the MAPT did not show benefits of
a combined multidomain and omega-3 fatty acid intervention to the primary cognitive outcomes, some cognitive improvements were seen for secondary outcomes and
subgroup analyses. Currently, the SYNchronizing Exercises, Remedies in Gait and Cognition (SYNERGIC) trial
is underway to investigate whether a 20-week multimodal
intervention combining aerobic and resistance training
exercise, with or without cognitive training or vitamin D
supplementation, can improve cognition and reduce falls
in 200 adults with mild cognitive impairment.91 Similar to
the current study, the SYNERGIC trial is focused on interventions that simultaneously target cognitive health and
physical function. A common element of these studies
is that they have incorporated cognitive training in the
11
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and omega-6 PUFAs in a healthy adult population.88 The
questionnaire includes main food sources of α-linolenic
acid as well as omega-6 PUFA, linoleic acid (LA) and
arachidonic acid (AA). The PUFA questionnaire consists
of 38 questions relating to the usual dietary habits related
to PUFA intake over 3 months. The questions pertain to
foods, such as fish, meat and eggs for omega-3 PUFA, and
vegetable oils and fats for omega-6 PUFA. The questionnaire covers fish oil supplement consumption and products with added omega-3 such as bread, eggs and milk.
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